Citations

Showing 10 of 108083 citations.

Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis
Choroszy, Marcin , Litwinowicz, Kamil , Bednarz, Robert S. , Sawicka, Emilia , Niemira, Magdalena , Sobieszczańska, Beata , Bednarz, Robert , Kamiński, Karol , Sawicka-Śmiarowska, Emilia , Niemira, Magdalena , Sobieszczańska, Beata , Roleder, Tomasz , Lerman, Amir , Toya, Takumi

Mayo Clinic

Metabolites | November 23, 2022 | Volume: 12 | Issue: 12 | Pages: 1165

10.3390/metabo12121165 | PMID 36557203 Get It

In recent years, the importance of the gut microbiome in human health and disease has increased. Growing evidence suggests that gut dysbiosis might be a crucial risk factor for coronary artery disease (CAD). Therefore, we conducted a systematic review and meta-analysis to determine whether or not CAD is associated with specific changes in the gut microbiome. The V3–V4 regions of the 16S rDNA from fecal samples were analyzed to compare the gut microbiome composition between CAD patients and controls. Our search yielded 1181 articles, of which 21 met inclusion criteria for systematic review and 7 for meta-analysis. The alpha-diversity, including observed OTUs, Shannon and Simpson indices, was significantly decreased in CAD, indicating the reduced richness of the gut microbiome. The most consistent results in a systematic review and meta-analysis pointed out the reduced abundance of Bacteroidetes and Lachnospiraceae in CAD patients. Moreover, Enterobacteriaceae, Lactobacillus, and Streptococcus taxa demonstrated an increased trend in CAD patients. The alterations in the gut microbiota composition are associated with qualitative and quantitative changes in bacterial metabolites, many of which have pro-atherogenic effects on endothelial cells, increasing the risk of developing and progressing CAD.
Stress, Cardiovascular Diseases and Exercise – A Narrative Review
Popović, Dejana , Lavie, Carl J., Lavie, Carl J.

Mayo Clinic

Heart and Mind | November 23, 2022 | Volume: 7 | Issue: 1 | Pages: 18-24

10.4103/hm.hm_33_22 Get It

The assuredness that adverse life stressors can lead to major negative impacts on an individual's health has been held since antiquity. Stress is considered a state of homeostasis being challenged, with biological consequences that can cause cardiovascular diseases (CVD). Stressors may be diverse and include a variety of psychological stressors, such as family stress, job strain, effort-award imbalance, long working hours, insecurity, social isolation, and lack of purpose in life. However, stressors may also be physical, immunological, metabolic, or environmental. Type of personality, anxiety, depression, pessimism or hostility, previous experience, genomics, body composition, nutritive and training status modulate stress responses and are important co-stressors. Chronic stress is linked with altered neurohormonal activity, which increases apoptotic pathways in cardiomyocytes. These pathways contribute to impaired myocardial contractility, increased risk of myocardial ischemia, infarction, heart failure, and arrhythmias. While stress is a vital risk factor for CVD, it has not been a major focus of preventive strategies. The purpose of this article is to review the impact of stress on CVD risk with an emphasis on approaches for stress reduction. Strength and endurance exercise, although being stress itself, leads to better adaptiveness to other types of stress, and by far has played an inevitable role in CVD risk reduction. Innovative strategies to combat CVD are strongly needed and exercise may be the best population-level cost-effective approach.
Current evidence on posthepatectomy liver failure: comprehensive review
Sparrelid, Ernesto , Dasari, B. , Erdmann, Joris I. , Santol, Jonas , Gilg, Stefan , Dasari, Bobby V M , Erdmann, Joris I , Santol, Jonas , Olthof, Pim , Starlinger, Patrick

Mayo Clinic

BJS Open | November 23, 2022 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/bjsopen/zrac142 | PMID 36415029 Get It

AbstractIntroductionDespite important advances in many areas of hepatobiliary surgical practice during the past decades, posthepatectomy liver failure (PHLF) still represents an important clinical challenge for the hepatobiliary surgeon. The aim of this review is to present the current body of evidence regarding different aspects of PHLF.MethodsA literature review was conducted to identify relevant articles for each topic of PHLF covered in this review. The literature search was performed using Medical Subject Heading terms on PubMed for articles on PHLF in English until May 2022.ResultsUniform reporting on PHLF is lacking due to the use of various definitions in the literature. There is no consensus on optimal preoperative assessment before major hepatectomy to avoid PHLF, although many try to estimate future liver remnant function. Once PHLF occurs, there is still no effective treatment, except liver transplantation, where the reported experience is limited.DiscussionStrict adherence to one definition is advised when reporting data on PHLF. The use of the International Study Group of Liver Surgery criteria of PHLF is recommended. There is still no widespread established method for future liver remnant function assessment. Liver transplantation is currently the only effective way to treat severe, intractable PHLF, but for many indications, this treatment is not available in most countries.
Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1‐CDG)
Altassan, Ruqaiah , Albert, Dimpna C. , Al-Owain, Mohammad, Al‐Halees, Zohair , Jaeken, Jaak , Morava, Éva , Morava, Eva

Mayo Clinic

JIMD Reports | November 22, 2022 | Volume: 64 | Issue: 2 | Pages: 123-128

10.1002/jmd2.12350 | PMID 36873091 Get It

AbstractWe report successful heart transplantation in a phosphoglucomutase 1 deficient (PGM1‐CDG) patient. She presented with facial dysmorphism, bifid uvula and structural heart defects. Newborn screening was positive for classic galactosemia. The patient was on a galactose‐free diet for 8 months. Eventually, whole exome sequencing excluded the galactosemia and revealed PGM1‐CDG. Oral D‐galactose therapy was started. Rapid deterioration of the progressive dilated cardiomyopathy prompted heart transplantation at the age of 12 months. Cardiac function was stable in the first 18 months of follow‐up, and hematologic, hepatic, and endocrine laboratory findings improved during D‐galactose therapy. The latter therapy improves several systemic symptoms and biochemical abnormalities in PGM1‐CDG but does not correct the heart failure related to cardiomyopathy. Heart transplantation has so far only been described in DOLK‐CDG.
Arrhythmic risk assessment of mitral valve prolapse pre- and post-mitral surgery—Authors’ reply
Sabbag, Avi , Essayagh, Benjamin , Enriquez‐Sarano, Maurice , Haugaa, Kristina H. , Haugaa, Kristina , Enriquez-Sarano, Maurice , Essayagh, Benjamin , Sabbag, Avi

Mayo Clinic

EP Europace | November 22, 2022 | Volume: 25 | Issue: 2 | Pages: 778-779

10.1093/europace/euac209 | PMID 36413621 Get It

Antibiotic Prophylaxis in Dentistry
Thornhill, Martin H. , Prendergast, Bernard , Lockhart, Peter B. , Baddour, Larry M. , Baddour, Larry , Thornhill, M H , Dayer, Mark

Mayo Clinic

Clinical Infectious Diseases | November 22, 2022 | Volume: 76 | Issue: 5 | Pages: 960-961

10.1093/cid/ciac857 | PMID 36413595 Get It

Network Model Compensation For Single-Point Measurements Of Multi-Pin Devices When Using Non-Invasive Current Estimation
Smutzer, Chad M., Keuseman, Jordan R., Haider, Clifton R. , Gilbert, Barry K.

Mayo Clinic

2022 IEEE 31st Conference on Electrical Performance of Electronic Packaging and Systems (EPEPS) | November 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-3

10.1109/epeps53828.2022.9947165 Get It

Review of Postoperative Respiratory Depression: From Recovery Room to General Care Unit
Weingarten, Toby N. , Šprung, Juraj

Mayo Clinic

Anesthesiology | November 22, 2022 | Volume: 137 | Issue: 6 | Pages: 735-741

10.1097/aln.0000000000004391 | PMID 36413782 Get It

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Sonneveld, Pieter , Chanan‐Khan, Asher , Nooka, Ajay K. , Beksaç, Meral , Hungria, Vânia , Munder, Markus , Mateos, María‐Victoria , Ahmadi, Tahamtan , Qin, Xiang , Mayo, Wendy Garvin, Gai, Xue , Carey, Jodi, Carson, Robin, Spencer, Andrew , Nooka, Ajay K , Masszi, Tamas , Beksac, Meral , Hungria, Vania , Munder, Markus , Mateos, María-Victoria , Mark, Tomer M , Levin, Mark-David , Gai, Xue , Spencer, Andrew , Weisel, Katja C , Masszi, Tamás , Špıčka, Ivan

Mayo Clinic

Journal of Clinical Oncology | November 22, 2022 | Volume: 41 | Issue: 8 | Pages: 1600-1609

10.1200/jco.21.02734 | PMID 36413710 Get It

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).